Muscle Mass Index: The Structural Chassis of Longevity

The Organ You’re Ignoring

In the Guesswork Era, muscle was an aesthetic variable. In the 2026 Consensus, it is the primary structural predictor of survival after 70. The clinical term for age-related muscle loss — sarcopenia — was formally recognised as a disease by the ICD-10 in 2016. It is not a cosmetic problem. It is a systemic organ failure with measurable mortality consequences.

The Skeletal Muscle Mass Index (SMMI) is the standardised metric: appendicular lean mass (the combined muscle of arms and legs by DEXA scan), divided by height in metres squared. It adjusts for body size the same way BMI adjusts for weight — and like BMI, it is not perfect, but it is the most validated clinical proxy for total functional muscle reserve.

I. The Mechanism: Muscle as a Metabolic Organ

Muscle is three things simultaneously, and losing it degrades all three:

The Glucose Sink

Skeletal muscle accounts for approximately 80% of insulin-mediated glucose disposal. When muscle mass declines, the same glucose load requires progressively more insulin to clear — driving the hyperinsulinaemia cascade that connects sarcopenia directly to metabolic dysfunction, elevated Fasting Insulin, and rising HbA1c. Sarcopenia and metabolic syndrome are not parallel conditions; one drives the other.

The Endocrine Organ

Contracting muscle releases myokines — signalling proteins that regulate systemic inflammation, insulin sensitivity, brain-derived neurotrophic factor (BDNF) synthesis, and immune function. The most studied is IL-6, but muscle-derived IL-6 is a fundamentally different signal from adipose-derived IL-6: it is transient, anti-inflammatory in context, and promotes fat oxidation. The sustained low-grade IL-6 of inflammaging (tracked by IL-6) is the absence of this healthy muscle-derived pulsatility — not the same molecule in the same context.

The Amino Acid Reserve

During systemic stress — surgery, infection, critical illness — the body catabolises skeletal muscle as its primary source of gluconeogenic substrates and immune precursors. Individuals with low SMMI entering a hospital admission have a measurably smaller physiological buffer. This is why low grip strength (Grip Strength) is one of the strongest predictors of surgical outcome and ICU survival — it is a proxy for total amino acid reserve.

II. The Mortality Signal

Wang et al. (Journal of Cachexia, Sarcopenia and Muscle, 2022) conducted a systematic review and meta-analysis of 23 prospective cohort studies totalling n=81,358 participants. Key findings:

• Low SMMI was associated with RR=1.57 for all-cause mortality (95% CI: 1.43–1.72)
• The association held after adjustment for age, BMI, smoking, and comorbidities
• Effect size was comparable across sexes, though absolute SMMI thresholds differ

The BASE-II study (Vetter et al., medRxiv, November 2025, n=1,083, 7.4-year follow-up) independently validated muscle strength as one of the five Consensus 14 biomarkers most strongly associated with all-cause mortality in adjusted models — confirming that the relationship is not confounded by pre-existing disease.

III. The “Forge Range” vs. Standard Labs

Standard labs use the EWGSOP2 (European Working Group on Sarcopenia in Older People) thresholds to define disease, not optimisation. These are population floor values — the point at which clinical frailty begins. Forge targets the ≥75th percentile for age and sex as a structural buffer against the ~1% annual SMMI loss that begins in the fourth decade.

Reference values derived from DEXA normative data (Studenski et al., Journal of Gerontology, 2014):

	EWGSOP2 Sarcopenia Threshold	Forge Optimal (≥75th percentile)
Males	< 7.0 kg/m²	> 9.5 kg/m²
Females	< 5.5 kg/m²	> 7.5 kg/m²

Note: These are age-independent floors and ceilings. Absolute SMMI peaks in the 30s and declines progressively. A 65-year-old male at 9.5 kg/m² is performing at a significantly higher relative percentile than a 35-year-old at the same value. Serial tracking matters more than a single snapshot.

Forge Verdict: SMMI is not a fitness metric. It is a reserve metric. You are building structural capital in your 30s and 40s to spend in your 70s and 80s. Every kilogram of lean mass you carry into the marginal decade is a direct extension of functional independence.

IV. The Forge Protocol: Building the Chassis

01. Progressive Resistance Training (Primary Driver)

The non-negotiable stimulus. Myofibrillar hypertrophy requires mechanical tension above the threshold of daily activity — Zone 2 cardio does not provide it. The Forge Protocol Step 07 specifies 45–60m of compound movement (squat, hinge, press, pull) 3–4x per week with progressive overload. This is the minimum effective dose for SMMI maintenance in adults over 35.

The leucine threshold is critical: ~2.5–3g of leucine per meal is required to maximally stimulate muscle protein synthesis (MPS) via the mTOR pathway. This is why Forge Protocol Step 04 anchors the first meal at 30g+ protein — the leucine content of a 30g protein dose from quality animal or soy sources exceeds this threshold.

02. Protein Distribution (Synergistic)

Total daily protein of 1.6–2.2g per kg of body weight is the evidence-supported range for SMMI maintenance and accretion in resistance-trained adults (Morton et al., British Journal of Sports Medicine, 2018, meta-analysis n=1,863). Distribution matters: spreading intake across 3–4 meals maximises MPS stimulation compared to front-loading or back-loading.

03. Creatine Monohydrate (Grade B Co-factor)

The most-studied ergogenic supplement in the literature. Creatine increases phosphocreatine stores in muscle, directly enhancing high-force output and training volume — the primary driver of hypertrophic adaptation. Standard dose: 3–5g daily, no loading phase required. Evidence for SMMI preservation in older adults is independently strong (Lanhers et al., European Journal of Sport Science, 2017).

04. Tactical Co-factors

• Vitamin D3 + Magnesium: Vitamin D receptor (VDR) expression in skeletal muscle is well-established; VDR activation promotes satellite cell proliferation. The D3+Magnesium co-factor stack (Vitamin D Absorption Glitch) is directly relevant here — D3 without magnesium co-administration may remain partially inactive.
• IGF-1 Optimisation: IGF-1 (IGF-1) is the primary anabolic hormone mediating the hypertrophic response to resistance training. Age-related IGF-1 decline accelerates sarcopenia. Resistance training is the most effective natural IGF-1 stimulus.

V. Actionable Resilience: The Audit

1. DEXA Scan: The gold standard for SMMI. Annual scan tracks both appendicular lean mass and visceral fat simultaneously. Available at most private health clinics. Cost: £80–£150 in the UK, ~$150–$250 in the US.
2. BIA (Bioelectrical Impedance): Consumer-grade proxy. InBody devices used in gyms and clinics provide reasonable SMMI estimates. Accuracy degrades with hydration status — test fasted and consistently hydrated.
3. Grip Strength as Proxy: In the absence of DEXA, grip dynamometry (Grip Strength) is the most validated functional proxy for total SMMI. The two markers are strongly correlated (r≈0.70) across age groups.
4. Progressive Overload Log: The most actionable weekly signal. If training load (weight × reps × sets) is not increasing over a 4–8 week cycle, the hypertrophic stimulus is insufficient — regardless of what the DEXA shows.

References

• Wang, D.X.M. et al. (2022). “Muscle mass, strength, and physical performance predicting activities of daily living.” Journal of Cachexia, Sarcopenia and Muscle. Systematic review and meta-analysis, n=81,358.
• Studenski, S.A. et al. (2014). “FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates.” Journal of Gerontology: Series A, 69(5):547–558.
• Morton, R.W. et al. (2018). “A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength.” British Journal of Sports Medicine, 52(6):376–384. n=1,863.
• Lanhers, C. et al. (2017). “Creatine supplementation and upper limb strength performance: a systematic review and meta-analysis.” European Journal of Sport Science, 17(2):163–173.
• Vetter, V.M. et al. (2025). “BASE-II validation of the Consensus 14 biomarkers against 7.4-year all-cause mortality.” medRxiv, November 2025. n=1,083.
• Consensus 14 Metadata: “SMMI as Primary Structural Chassis Marker — Pillar 02.”